CTT Pharmaceutical Holdings, Inc. CEO and Director Ryan Khouri filed a statement of changes in beneficial ownership on November 16, 2026, disclosing a purchase of common stock on November 12, 2026.
Key Highlights
- Reporting person: CTT Pharmaceutical Holdings, Inc., signed by Ryan Khouri, who serves as both CEO and Director.
- Transaction: 1,500 shares of CTTH common stock acquired (transaction code P) on November 12, 2026.
- Price paid: $0.054 per share, according to the filing.
- Resulting ownership: 9,454,036 shares of CTTH beneficially owned directly following the transaction.
- Filing date: November 16, 2026, filed by one reporting person.
Ryan Khouri's November 2026 Open-Market Purchase of CTTH Shares
According to the filing, Ryan Khouri, who holds the roles of CEO and Director at CTT Pharmaceutical Holdings, Inc. (OTC:CTTH), purchased 1,500 shares of the company's common stock on November 12, 2026, at a price of $0.054 per share. The transaction is coded "P," indicating an open-market purchase. CTT Pharmaceutical Holdings, Inc. is the issuer named in the filing, with its ticker listed as CTTH and its address on record as 1646 W. Snow Ave Suite 138, Tampa, Florida 33606.
Following the reported purchase, the filing discloses that the reporting person directly beneficially owns 9,454,036 shares of CTTH. No derivative securities transactions were reported in Table II of the filing. The form was filed by one reporting person and was not indicated as an amendment to a prior filing. No Rule 10b5-1(c) plan designation was checked on the form, according to the disclosure.
What Was Disclosed
The filing disclosed a single open-market purchase of 1,500 CTTH shares at $0.054 per share by CEO and Director Ryan Khouri on November 12, 2026, resulting in direct beneficial ownership of 9,454,036 shares. No derivative securities activity was reported.



Please wait processing your request...